Johnson & Johnson's Animas is moving forward with its investigational artificial pancreas--an insulin-delivery device that can detect blood glucose in the body and automatically normalize levels.
Bloomberg reports that J&J is close to settling with the U.S. Justice Department for up to $2.2 billion. At that amount, the settlement would rank second to Pfizer's $2.3 billion off-label marketing deal from 2009.
Johnson & Johnson's ($JNJ) Animas will advance a second feasibility study for its artificial pancreas system, after the system generated promising results from first trial effort involving 13 adult patients with Type 1 diabetes.
Johnson & Johnson didn't disappoint close observers of the diabetes drug development field with its battery of late-stage results for the experimental diabetes drug canagliflozin.
Determined to build its stake in the fast-growing diabetes market, Johnson & Johnson plans to showcase late-stage data this weekend on its promising SGLT2 drug candidate that has drawn both praise and skepticism from clinicians and analysts.
Private-label products still take the place of Tylenol and other McNeil products on store shelves, and patients aren't happy about it.
Johnson & Johnson/Ethicon ($JNJ) will stop selling four vaginal mesh implants in the face of hundreds of lawsuits challenging the products' safety.
After last year's debut of Dendreon's immunotherapy Provenge and Johnson & Johnson's pill Zytiga, prostate cancer treatment may be in for another big shake-up.
As Goldman Sachs analyst Jami Rubin sees it, there's another major drugmaker whose whole is worth less than the sum of its parts. This time, it's Johnson & Johnson--and Rubin figures it would be worth more split three ways.
Bayer looks to secure blockbuster status for regorafenib; J&J demonstrated impressive results among pre-chemo prostate cancer patients; Aveo raises the flag for tivozanib; Seattle Genetics plans to look at new indications for Adcetris.